Nemo-Like Kinase anticorps (AA 278-527)

N° du produit ABIN7169125

Détail du produit anti-Nemo-Like Kinase anticorps

Antigène: Nemo-Like Kinase (NLK)

Épitope: AA 278-527

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp Nemo-Like Kinase est non-conjugé

Application: Western Blotting (WB), ELISA, Immunohistochemistry (IHC)

Réactivité croisée: Humain

Purification: Antigen Affinity Purified

Immunogène: Recombinant Human Serine/threonine-protein kinase NLK protein (278-527AA)

Isotype: IgG

Information d'application

Indications d'application: Recommended dilution: WB:1:1000-1:5000, IHC:1:20-1:200,

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: PBS with 0.02 % sodium azide, 50 % glycerol, pH 7.3.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C,-80 °C

Stockage commentaire: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Détails sur Nemo-Like Kinase

Antigène: Nemo-Like Kinase (NLK)

Autre désignation: NLK (NLK Produits)

Synonymes: anticorps Amf, anticorps Gpi1, anticorps AI194375, anticorps nlk, anticorps nlkb, anticorps zgc:111875, anticorps Xnlk, anticorps nlk1, anticorps nlk2, anticorps NLK, anticorps nemo-like, anticorps RGD1561602, anticorps glucose-6-phosphate isomerase, anticorps nemo like kinase, anticorps nemo-like kinase, type 1, anticorps nemo-like kinase L homeolog, anticorps Nemo-Like kinase, anticorps nemo-like kinase, anticorps Gpi, anticorps NLK, anticorps Nlk, anticorps nlk1, anticorps nlk.L, anticorps nlk, anticorps nemo-like

Sujet:

Background: Serine/threonine-protein kinase that regulates a number of transcription factors with key roles in cell fate determination. Positive effector of the non-canonical Wnt signaling pathway, acting downstream of WNT5A, MAP3K7/TAK1 and HIPK2. Activation of this pathway causes binding to and phosphorylation of the histone methyltransferase SETDB1. The NLK-SETDB1 complex subsequently interacts with PPARG, leading to methylation of PPARG target promoters at histone H3K9 and transcriptional silencing. The resulting loss of PPARG target gene transcription inhibits adipogenesis and promotes osteoblastogenesis in mesenchymal stem cells (MSCs). Negative regulator of the canonical Wnt/beta-catenin signaling pathway. Binds to and phosphorylates TCF7L2/TCF4 and LEF1, promoting the dissociation of the TCF7L2/LEF1/beta-catenin complex from DNA, as well as the ubiquitination and subsequent proteolysis of LEF1. Together these effects inhibit the transcriptional activation of canonical Wnt/beta-catenin target genes. Negative regulator of the Notch signaling pathway. Binds to and phosphorylates NOTCH1, thereby preventing the formation of a transcriptionally active ternary complex of NOTCH1, RBPJ/RBPSUH and MAML1. Negative regulator of the MYB family of transcription factors. Phosphorylation of MYB leads to its subsequent proteolysis while phosphorylation of MYBL1 and MYBL2 inhibits their interaction with the coactivator CREBBP. Other transcription factors may also be inhibited by direct phosphorylation of CREBBP itself. Acts downstream of IL6 and MAP3K7/TAK1 to phosphorylate STAT3, which is in turn required for activation of NLK by MAP3K7/TAK1. Upon IL1B stimulus, cooperates with ATF5 to activate the transactivation activity of C/EBP subfamily members. Phosphorylates ATF5 but also stabilizes ATF5 protein levels in a kinase-independent manner (PubMed:25512613).

Aliases: DKFZp761G1211 antibody, FLJ21033 antibody, LAK1 antibody, Nemo like kinase antibody, Nemo-like kinase antibody, Nlk antibody, NLK_HUMAN antibody, Protein LAK1 antibody, Serine/threonine protein kinase NLK antibody, Serine/threonine-protein kinase NLK antibody

UniProt: Q9UBE8

Pathways: Ubiquitin Proteasome Pathway